论文部分内容阅读
目的分析CK19和Galectin-3在甲状腺乳头状微小癌(PMCT)中的表达状况,了解这两种抗体组合对PMCT的早期诊断及鉴别诊断的临床价值,并探讨临床手术术式的选择及预后。方法采用免疫组化方法检测23例中CK19和Galectin-3的表达情况,并术后随访2～72个月。结果CK19和Galectin-3在23例PMCT中阳性表达率分别为91.31%和95.66%,23例患者中行患侧甲状腺腺叶或次全切除15例,双侧甲状腺腺叶切除6例,患侧甲状腺全切加峡部加对侧甲状腺次全切除2例;随访观察,除2例失访,其余21例患者均健在无复发或死亡。结论CK19和Galectin-3对PMCT的早期诊断及与甲状腺良性病变的鉴别诊断具有显著作用。PMCT预后较好,对于偶然发现或低危的PMCT可行甲状腺腺叶或甲状腺次全切除术,并保持临床长期随访观察。
Objective To analyze the expression of CK19 and Galectin-3 in papillary thyroid carcinoma (PMCT), and to understand the clinical value of the combination of these two antibodies in the early diagnosis and differential diagnosis of PMCT. To explore the selection and prognosis of surgical operation. Methods The expression of CK19 and Galectin-3 in 23 cases were detected by immunohistochemistry and were followed up for 2 to 72 months. Results The positive expression rates of CK19 and Galectin-3 in 23 cases of PMCT were 91.31% and 95.66% respectively. Twenty-three patients underwent ipsilateral thyroid gland or subtotal resection in 15 cases, bilateral thyroidectomy in 6 cases, ipsilateral thyroid gland Total resection of the isthmus and the contralateral thyroid subtotal resection in 2 cases; follow-up observation, in addition to two cases were lost, the remaining 21 patients were alive without recurrence or death. Conclusion CK19 and Galectin-3 have a significant effect on the early diagnosis of PMCT and the differential diagnosis of benign thyroid lesions. The prognosis of PMCT is good, and it is feasible to observe the long-term clinical follow-up of thyroid gland or subtotal thyroidectomy for PMCT by accident or low risk.